ArticleJournal of clinical and experimental hepatology
The Canadian Hepatopulmonary Syndrome Program: A Longitudinal Liver Transplant Experience.
Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Hepatopulmonary syndrome (HPS) is a pulmonary complication of liver disease comprised of liver dysfunction, intrapulmonary vascular dilatations, and abnormal oxygenation. Liver transplantation (LT) is the only curative treatment for HPS, but outcome reports in objectively diagnosed cohorts are mostly from single centers with mild/moderate disease populations and short-term follow-up. Methods: This was a retrospective cohort study in which we sought to describe short- and long-term LT outcomes and their predictors in the Canadian HPS Program. Results: Among 53 patients with HPS receiving LT (partial pressure of arterial oxygen [PaO Conclusion: We present LT data in the most severe and among the largest and longest-followed HPS cohorts reported to date. Our favorable outcomes compared to smaller centers and large databases suggest that high-volume centers with HPS expertise are preferable for LT in severe/very severe HPS. Heightened vigilance for specific short-term complications along with close monitoring of patients with comorbid obstructive lung disease is indicated. Our detailed analysis of post-transplant events and time course of disease resolution/oxygen cessation can inform patient/family counseling and provider expectations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.